Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 6,534 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Subject Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg

NCT00650065
View directory record Official record
Conditions
Healthy
Interventions
Cetirizine HCl Tablets 10 mg, Zyrtec® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 12:20 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

NCT05366439
View directory record Official record
Conditions
Dengue
Interventions
AT-752, Placebo Comparator
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

NCT03918239
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SHP643
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Metolazone Tablets 10 mg and Zaroloxyn® Tablets 10 mg

NCT00650195
View directory record Official record
Conditions
Healthy
Interventions
Metolazone Tablets 10 mg, Zaroloxyn® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT04551677
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 84 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

NCT02873156
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2027, E2027 matched placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 22, 2026, 12:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Fructose Intestinal Gluconeogenesis

NCT07209202
View directory record Official record
Conditions
Healthy Participants, Obese But Otherwise Healthy Participants
Interventions
High fructose meal, Low fructose meal, 13C labeled fructose, oral, 13C labeled fructose, intravenous
Other
Lead sponsor
Touro University, California
Other
Eligibility
20 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Vallejo, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 22, 2026, 12:20 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Inflammatory and Metabolic Responses to Long-term Dietary Supplementation With Anthocyanin-rich Blend

NCT04637945
View directory record Official record
Conditions
Anthocyanins
Interventions
ACRB, Placebo
Dietary Supplement · Other
Lead sponsor
Pharmanex
Industry
Eligibility
18 Years to 35 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants

NCT04234672
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion, [14C]TAK-831 Oral Suspension
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Canagliflozin and Metformin Immediate Release (50 mg/500 mg) FDC Tablets in Healthy Volunteers

NCT01508195
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin tablets, Metformin IR tablets, Canagliflozin/metformin IR FDC tablets
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices

NCT03267511
View directory record Official record
Conditions
Oral Hygiene
Interventions
5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica, 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP, 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica, 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers

NCT00279734
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tetanus + pnemococcal vaccines alone, Abatacept + Vaccines
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
Lenexa, Kansas • Baltimore, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Absolute Oral Bioavailability of Remimazolam

NCT04113564
View directory record Official record
Conditions
Bioavailability
Interventions
Remimazolam
Drug
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]

NCT00823407
View directory record Official record
Conditions
Healthy
Interventions
MDA, Placebo
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacodynamic and Pharmacokinetic Study of RO5508887 in Healthy Volunteers

NCT01592331
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Placebo, RO5508887
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison Between Two Formulations of NN5401 in Healthy Subjects

NCT01125553
View directory record Official record
Conditions
Diabetes, Healthy
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 12:20 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Understanding Oral Nicotine Pouch Use in Healthy Volunteers

NCT07829939
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
0 mg oral nicotine pouches, 3 mg oral nicotine pouches, 6 mg oral nicotine pouches, cigarette or e-cigarette
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 12:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Immune Response to Booster Vaccines in Blood Transplant Patients and Healthy Volunteers

NCT00005907
View directory record Official record
Conditions
Active Immunity, Healthy, Stem Cell Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

NCT05234736
View directory record Official record
Conditions
Subcutaneous Fat
Interventions
CBL-514
Drug
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

NCT05293171
View directory record Official record
Conditions
Healthy Subjects
Interventions
1.25 mg/kg BL-8040 + BL-8040-matching placebo, 2 mg/kg BL-8040, BL-8040-matching placebo, 400 mg Moxifloxacin (1x400 mg tablet)
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 22, 2026, 12:20 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

NCT03276728
View directory record Official record
Conditions
Heart Failure, Healthy Volunteer
Interventions
AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
8
States / cities
Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 22, 2026, 12:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Mass Balance, Pharmacokinetics, Metabolism, and Excretion of Emraclidine in Healthy Adult Male Participants

NCT06301971
View directory record Official record
Conditions
Healthy Participants
Interventions
Emraclidine
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 22, 2026, 12:20 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease

NCT00886951
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
I123MNI388/I123MNI390
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 22, 2026, 12:20 PM EDT